Related Experiment Video
Updated: Jul 9, 2026

Protein Purification-free Method of Binding Affinity Determination by Microscale Thermophoresis
Published on: August 15, 2013
Structural basis for the binding of high affinity phosphopeptides to Stat3
1Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. jsmcmur@mdanderson.org
Abstract:
Signal transducer and activator of transcription 3 (Stat3) is constitutively active in a number of cancers where it participates in aberrant transcription of prosurvival, cell cycling, and angiogenesis genes. Since Stat3 initiates its signaling activity through binding of its SH2 domain to phosphotyrosine residues on cell surface receptors, inhibitors targeting this region of the protein are potential chemotherapeutic agents. To date, no NMR or X-ray crystallographic structures of high-affinity phosphopeptides complexed with the Stat3 SH2 domain are available to aid in the development of peptidomimetic antagonists. Examination of the crystal structures of several STAT proteins and the complex of Stat1 with Ac-pTyr-Asp-Lys-Pro-His-NH(2) led to a hypothesis that the specificity determinant for Stat3, glutamine at position pY+3 in pTyr-Xxx-Xxx-Gln sequences, resides in a unique pocket on the protein surface at the juncture of the third strand of the central beta-sheet and a unique, STAT specific alpha-helix. Docking of Ac-pTyr-Leu-Pro-Gln-NHBn to the SH2 domain of Stat3 using molecular modeling showed that the Gln binds tightly in this pocket and participates in a network of hydrogen bonds. Novel interactions between the peptide main chain and the protein were also discovered. Phosphopeptide structure-affinity studies using unnatural amino acids and glutamine derivatives provide evidence for the peptide-protein interactions revealed by the model and lend support to the binding hypothesis.
Insights
Targeting Signal transducer and activator of transcription 3 (Stat3) in cancer is crucial. This study reveals key binding interactions within the Stat3 SH2 domain, aiding the development of novel cancer therapeutics.
Area of Science:
- Oncology
- Molecular Biology
- Structural Biology
Background:
- Signal transducer and activator of transcription 3 (Stat3) is constitutively active in various cancers, promoting tumor growth.
- Stat3's SH2 domain binds phosphotyrosine residues, making it a target for cancer drug development.
Purpose of the Study:
- To elucidate the structural basis of phosphopeptide binding to the Stat3 SH2 domain.
- To identify key residues and interactions for designing Stat3 inhibitors.
Main Methods:
- Molecular modeling and docking of phosphopeptides to the Stat3 SH2 domain.
- Analysis of existing STAT protein crystal structures.
- Structure-affinity studies using modified peptides.
Main Results:
- A specific pocket in the Stat3 SH2 domain was identified, accommodating glutamine at position pY+3.
- Molecular modeling predicted tight binding of glutamine via hydrogen bonds.
- Experimental studies supported the predicted peptide-protein interactions.
Conclusions:
- The glutamine residue at pY+3 is a key specificity determinant for Stat3 SH2 domain binding.
- Understanding these interactions facilitates the design of targeted Stat3 peptidomimetic inhibitors for cancer therapy.
More Related Videos
Related Concept Videos
The JAK-STAT Signaling Pathway
Amplifying Signals via Enzymatic Cascade
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
PI3K/mTOR/AKT Signaling Pathway
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...

